Updated:
Centre for Commercialization of Regenerative Medicine
CCRM brings together stakeholders, expertise, infrastructure and funding to accelerate the development and commercialization of regenerative medicines.
Overview
CCRM brings together stakeholders, expertise, infrastructure and funding to accelerate the development and commercialization of regenerative medicines.
General information
Location
Region
North America
Country
Canada
City
Toronto
Corporate office
Montreal, Quebec, Canada
Additional offices
Vancouver · Toronto
Principals
Michael May
President and CEO
Sector focus
Frequently asked questions
Does CCRM make direct investments or only offer services?
CCRM creates and scales companies through its translational platforms and infrastructure, a hybrid of service provision and de facto company building. Its OmniaBio GMP facility and CCVP platform represent capital-intensive assets that support cell and gene therapy development.
What investment stages does CCRM target?
CCRM works primarily at the pre-commercial and early-stage interface, bridging academic research and industry. It focuses on technologies that address bottlenecks in regenerative medicine commercialization, often supporting ventures before they reach typical venture capital investment stages.
What sectors does CCRM explicitly focus on?
CCRM focuses exclusively on regenerative medicine, cell and gene therapies, and related advanced therapy technologies. It does not invest outside this therapeutic modality. Its DeepTech Bio Lab also incorporates AI, quantum, and data technologies to accelerate cell and gene therapy development.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: